

Targeted Case Management of CareOregon Members Prescribed Antidepressant and/or Antipsychotic Medications

OHREC Presentation - Wilsonville

Presenters: Judy Robison, Matt Carlson, Ann Hamer

October 15, 2003

Targeted Case Management Grant Team

Ann Hamer, OSU Clinical Pharmacist
Bruce Goldberg, CareOregon Medical Director
Carole Romm, CareOregon Health Partnerships Director
David Mosen, CareOregon Research Associate
Dean Haxby, CareOregon Pharmacy Director
Jon Puro, CareOregon Database Administrator
Judy Robison, CareOregon TCM Grant Project Manager
Kathy Ketchum, OSU College of Pharmacy Medicaid Program
Mark Spofford, MCHD Behavioral Health Program Manager
Matthew Carlson, CareOregon Research Associate
Peter Davidson, Multnomah County/Verity Medical Director
Rick Ralston, Legacy Good Samaritan Behavioral Health Manager
Rupert Goetz, Clackamas County/ MHO Medical Director

CareOregon's Pilot Sites

- Clackamas County Mental Health (CCMH)
- Legacy Good Samaritan NW Clinic
- Multnomah County Health Dept./NE Clinic

Targeted Case Management (TCM)*

Goals

- 1. Increase consultation between clinical pharmacists, primary care providers, and mental health professionals to improve medication management**
- 2. Implement Depression Recognition and Care Management in primary care pilot sites**

***State Office of Medicaid Assistance Programs (OMAP)
Grant Award #99927 - 2002-2003**

What Was Studied

Population Analysis

- Number of members, percent receiving antidepressant and/or antipsychotic medication
- Enrollment categories
- Effect of clinical pharmacy training/consult to improve medication management
- Effect of care management on patient care for depression in primary care

The Database

- Office of Medical Assistance Programs (OMAP) pharmacy and mental health utilization claims
- CareOregon enrollment and claims
 - Demographic characteristics
 - Eligibility categories
 - Outpatient utilization

**Figure 1: CareOregon Member Enrollment in MHOS
1/1/01 to 6/30/02**




Figure 2. Dually Enrolled Members Receiving an Antidepressant or Antipsychotic Medication 1/1/01 to 6/30/02





Figure 3. Percent of Members Receiving Antipsychotics or Antidepressants by Drug Type 1/1/01 to 6/30/02



Treating Depression In Primary Care

- Screening for depression improves outcomes (US Preventive Services Task Force 2002)
- 50% of patients stop medication within first 3 months*
- Medication often not used at dosage sufficient to give full remission*

Depression Recognition and Care Management Guidelines Pilot Sites

- **Multnomah County Health Dept NE Clinic**
- **Legacy Good Samaritan NW Clinic**

Care Manager Role

- Care management to monitor high risk medically ill patients with moderate to severe depression
- Reinforce patient instructions to increase treatment adherence through monitoring effects/side effects
- Problem solve with patients for emerging problems
- Facilitate patient referral to specialty mental health for complex cases

Appropriate Medication Management for Dually Enrolled Members with a New Prescription for Antidepressant Medication

	CareOregon	MHOs	HEDIS 2000 Medicaid %		
			25th	50th	75th
3 month Medication Adherence	45%	47%	39%	44%	50%
6 month Medication Adherence	27%	27%	24%	28%	36%
3 or more PCP visits in 3 months	34%	NA	10%	15%	26%

Pharmacist Consultation

- Offered at each site, primary focus at CCMH
- Clinical Pharmacist provided support to providers with challenging patients about multiple medications/multiple diagnoses
- Developed Psychopharmacology “Tidbits”

Pharmacy Intervention

- Pharmacy Education
 - All three sites (focus on primary care sites)
 - Topic: Appropriate utilization of antidepressants and dispelling industry rumors
- Provider Profiling
 - Patient profiles
 - Antidepressant utilization profile
 - Voluntary SSRI change order form

Pharmacy Intervention

- Voluntary SSRI Change Order Forms
 - Form sent to prescribers describing patients' antidepressant use and described cost effective alternatives
 - QD dosing, 1/2 tablets, generic fluoxetine
 - Distributed, collected and executed by primary care "care managers"

Figure 4. Average Monthly Costs Per Member for SSRI in Calendar Year 2002




Figure 5. Average Monthly Costs Per Member for Brand SSRIs and Fluoxetine




Figure 6. What Happened to Change Orders (n=211)




Figure 7. Accepted Change Orders by Type (n=48)




Figure 8. Reasons for Change Order Denial (n=54)




Table 1. Projected Cost Savings Based on Project Findings*

	Average Annual Cost Before Treatment	Average Annual Cost After	Total Estimated Cost Before	Total Estimated Cost After	Annual Projected Savings	% Annual Savings
Entire Sample	\$269	\$242	\$2,809,974	\$2,528,767	\$281,207	10%
Returned Change Orders	\$268	\$212	\$2,800,363	\$2,218,312	\$582,051	21%

* Because these are 2002 data, the OHP Standard Population is included.